#1 Clinical Trials Search in Europe

Regadenoson

This article explores the use of Regadenoson, also known as Lexiscan, in various clinical trials focused on cardiac imaging and stress testing. Regadenoson is a pharmacological stress agent used to assess coronary artery disease and myocardial perfusion. The trials investigate its effectiveness, safety, and potential applications in different cardiac imaging modalities, including PET, MRI, and CT scans.

Table of Contents

What is Regadenoson?

Regadenoson, also known by its brand name Lexiscan, is a medication used primarily in cardiac imaging tests[1]. It belongs to a class of drugs called adenosine A2A receptor agonists[2]. Regadenoson is designed to temporarily increase blood flow in the heart, which is crucial for certain diagnostic procedures.

How Regadenoson Works

Regadenoson works by selectively activating adenosine A2A receptors in the body. This activation causes the coronary arteries (the blood vessels that supply the heart muscle) to dilate or widen[3]. When these arteries dilate, more blood can flow through them. This increased blood flow is essential for imaging tests that aim to detect blockages or other problems in the heart’s blood vessels.

Medical Uses of Regadenoson

Regadenoson is primarily used in the following medical contexts:

  • Myocardial Perfusion Imaging: This is a type of heart scan that shows how well blood flows through the heart muscle. Regadenoson is used to simulate the effects of exercise on the heart for patients who cannot perform physical exercise[1].
  • Coronary Artery Disease Detection: By increasing blood flow in the heart, Regadenoson can help doctors identify areas of the heart that aren’t receiving enough blood due to narrowed or blocked arteries[1].
  • Evaluation of Chest Pain: In emergency settings, Regadenoson may be used to help determine if chest pain is caused by coronary artery disease[1].
  • Lung Transplantation: Research is being conducted to see if Regadenoson can help improve the function of donor lungs before transplantation[2].

How Regadenoson is Administered

Regadenoson is typically administered in the following way:

  • It is given as a single intravenous (IV) injection, usually in a dose of 0.4 mg[1].
  • The injection is typically given over a period of about 10 seconds[4].
  • After the injection, a saline flush is usually given to ensure all of the medication enters the bloodstream[4].
  • The effects of Regadenoson are rapid, usually peaking within 1-2 minutes after injection[1].

Potential Side Effects

Like all medications, Regadenoson can cause side effects. Common side effects may include:

  • Shortness of breath
  • Headache
  • Flushing
  • Chest discomfort
  • Dizziness
  • Nausea

These side effects are usually mild and short-lived, typically resolving within 15-30 minutes[3]. However, it’s important to inform your healthcare provider if you experience any unusual or severe side effects.

Ongoing Research and Future Applications

Researchers are exploring new potential uses for Regadenoson:

  • Lung Transplantation: Studies are investigating whether Regadenoson can help improve the function of donor lungs before transplantation, potentially increasing the number of viable donor lungs[2].
  • Predicting Sudden Cardiac Death: Research is being conducted to determine if a patient’s heart rate response to Regadenoson could help predict the risk of sudden cardiac death[3].
  • Pulmonary Hypertension: Scientists are exploring whether Regadenoson could be useful in testing for pulmonary hypertension, a condition of high blood pressure in the lungs[5].
  • Advanced Imaging Techniques: Researchers are investigating the use of Regadenoson with newer imaging technologies like PET-MRI (Positron Emission Tomography-Magnetic Resonance Imaging) to improve the diagnosis of heart conditions[4].

These ongoing studies may lead to new applications for Regadenoson in the future, potentially expanding its role in diagnosing and treating various heart and lung conditions.

Aspect Details
Primary Use Pharmacological stress agent for cardiac imaging
Administration Intravenous injection, typically 0.4 mg bolus
Imaging Modalities PET, MRI, CT
Key Advantages Rapid administration, short duration of action
Main Applications Assessing coronary artery disease, myocardial perfusion
Safety Profile Generally well-tolerated, some cardiovascular side effects
Research Focus Diagnostic accuracy, protocol optimization, comparison with other stress agents
Potential Benefits Improved diagnosis of CAD, reduced need for invasive procedures

FAQ

  • What is Regadenoson and how is it used in cardiac imaging? Regadenoson (also known as Lexiscan) is a pharmacological stress agent used in cardiac imaging. It is administered intravenously to simulate the effects of exercise on the heart, allowing doctors to assess blood flow to the heart muscle and detect coronary artery disease.
  • What are the advantages of using Regadenoson over other stress agents? Regadenoson offers several advantages, including its ability to be administered as a single, rapid injection rather than a prolonged infusion. This makes it easier to use during imaging procedures and potentially more comfortable for patients. It also has a relatively short duration of action, which can be beneficial for patient safety and comfort.
  • In which imaging modalities is Regadenoson being studied? Clinical trials are investigating the use of Regadenoson in various cardiac imaging modalities, including Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT) scans. These studies aim to determine its effectiveness and potential applications across different imaging techniques.
  • What are some potential risks or side effects of Regadenoson? While Regadenoson is generally well-tolerated, it can cause side effects such as shortness of breath, headache, flushing, chest discomfort, and changes in heart rate or blood pressure. Patients with certain conditions like severe COPD or unstable angina may be at higher risk for complications. Always consult with a healthcare provider about potential risks and side effects.
  • How might Regadenoson improve the diagnosis of coronary artery disease? Regadenoson may improve the diagnosis of coronary artery disease by providing a standardized method of inducing stress on the heart during imaging procedures. This allows for better visualization of blood flow and potential blockages in the coronary arteries. Some studies are also investigating whether it can help identify patients who would benefit most from further invasive procedures or treatments.

Ongoing Clinical Trials on Regadenoson

  • Study on the Safety and Effects of Regadenoson and Gadobutrol in Heart Imaging for Children with Cardiovascular Conditions

    Recruiting

    1 1 1
    Investigated drugs:
    France Greece Italy

  • Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions

    Recruiting

    1 1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Germany Italy The Netherlands Poland

  • Study on Colchicine for Patients with Angina Symptoms and Coronary Microvascular Disease

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Prognostic H2[15O] PET Imaging Study in Patients with Coronary Artery Disease Using O15‑Water, Adenosine and Regadenoson

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Theophylline, Gadoteric Acid, and Regadenoson for Patients with Chronic Total Coronary Artery Blockage

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A Study of XC001 Gene Therapy with Bypass Surgery for Patients with Coronary Artery Disease and Weakened Heart Function at Risk for Incomplete Treatment

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary The Netherlands Poland

Glossary

  • Regadenoson: A pharmacological stress agent used in cardiac imaging to simulate the effects of exercise on the heart. It is administered intravenously and is also known by the brand name Lexiscan.
  • Myocardial Perfusion: The flow of blood to the heart muscle (myocardium). Assessing myocardial perfusion is crucial in diagnosing coronary artery disease and other heart conditions.
  • Coronary Artery Disease (CAD): A condition where the arteries that supply blood to the heart become narrowed or blocked, usually due to the buildup of plaque. This can lead to reduced blood flow to the heart muscle.
  • Positron Emission Tomography (PET): An imaging technique that uses small amounts of radioactive tracers to visualize and measure metabolic processes in the body, including blood flow to the heart.
  • Magnetic Resonance Imaging (MRI): A non-invasive imaging technique that uses strong magnetic fields and radio waves to create detailed images of organs and tissues in the body, including the heart.
  • Computed Tomography (CT): An imaging method that uses X-rays to create detailed cross-sectional images of the body, including the heart and coronary arteries.
  • Stress Test: A procedure that assesses how well the heart functions during physical activity or pharmacologically-induced stress, used to diagnose coronary artery disease and other heart conditions.
  • Myocardial Ischemia: A condition where there is reduced blood flow to the heart muscle, usually due to narrowed or blocked coronary arteries, which can lead to chest pain (angina) or heart attacks.
  • Fractional Flow Reserve (FFR): A measurement used during coronary angiography to determine the functional significance of a coronary artery stenosis by measuring pressure differences across a narrowed artery.
  • Implantable Cardioverter Defibrillator (ICD): A small device implanted in the chest to detect and correct abnormal heart rhythms, used to prevent sudden cardiac death in high-risk patients.

References

  1. https://clinicaltrials.gov/study/NCT01969916
  2. https://clinicaltrials.gov/study/NCT04521569
  3. https://clinicaltrials.gov/study/NCT01842035
  4. https://clinicaltrials.gov/study/NCT01779869
  5. https://clinicaltrials.gov/study/NCT02220634